References
- Bhat N, Wright JG, Broder KR, Murray EL, Greenberg ME, Glover MJ, Likos AM, Posey DL, Klimov A, Lindstrom SE, et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 2005; 353:2559-67; PMID:16354892; http://dx.doi.org/10.1056/NEJMoa051721
- Van Essen GA, Palache AM, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 2003; 21:1780-5; PMID:12686094; http://dx.doi.org/10.1016/S0264-410X(03)00072-0
- Li S Li L, Ai X, Yang L, Bai Y, Wang Z, Han H, Lu Q, Luo F, Zhang Z, et al. A randomized, controlled, blinded study of the safety, immunogenicity and batch consistency of Aleph inactivated split influenza vaccine made in China in Chinese people. Hum Vaccin Immunother 2014; 10 (3):1-9; PMID:24301228
- Launay O, Duval X, Fitoussi S, Jilg W, Kerdpanich A, Montellano M, Schwarz TF, Watanveerade V, Wenzel JJ, Zalcman G, et al. Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials. BMC Infect Dis 2013; 16(13):435; PMID:24041010; http://dx.doi.org/10.1186/1471-2334-13-435
- World Health Organization. Wkly Epidemiol Rec 2012; 87: 233-40; PMID:22715518
- Hehme NW, Künzel W, Petschke F, Türk G, Raderecht C, Van Hoecke C, Sänger R. Ten years of experience with the trivalent split-influenza vaccine, fluarix(TM). Clin Drug Investig 2002; 22:751-69; http://dx.doi.org/10.2165/00044011-200222110-00004
- Committee for Proprietary Medicinal Products (CPMP): Note for guidance on harmonisation of requirements for influenza vaccines. The European Agency for the Evaluation of Medicinal Products. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf
- Center for Biologics Evaluation and Research (CBER). Guidance for Industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Food and Drug Administration (FDA). http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf
- Wang L, Li J-J, Zu W-G, Cheng Y, Tian B. The analyze for Influenza cases in Bao Ding City. Mod Prevent Med; 2014(14)
- World Health Organization. Influenza Laboratory Surveillance Information by the Global Influenza Surveillance and Response System(GISRS). 2013.
- Cheng K, Shen X, Yang S, Zhou Z, Xie J, Chen W, Weng Y, Yan Y. Research on growth and decline of antibody in H1N1 vaccine serum. Chinese Zoonosis 2012; 06:566-9
- Liu X, Lv J, Yang M, Chen X. Immune effect analysis in Daxinganling crowd, Inner Mongolia with H1N1 influenza vaccine in 21 to 93 days. Contemp Med 2010; 27:159-60.
- Zheng K, Yang R, Zhang X, Huang R, Chai B. Immunization persistence evaluation of H1N1 influenza vaccine after one year. Prevent Med Infor 2012; 10:825-8
- Huang K, Ni Z, Cheng W. Mixed linear model application in repeated measurement data of clinical trials. Mod Prevent Med 2005; 11:166-7.
- Lamb RA, Krug RM. Orthomyxoviridae: The Virus and Their replication. In: Fields Virology, Editors-in-Chief: Knipe DM, Howley PM. 4th Edition. Philadelphia, PA: Lippincott Williams and Wilkins, Publishers; 2001:1487-531.